medigraphic.com

2018, Número 3

<< Anterior Siguiente >>

Rev Fac Med UNAM 2018; 61 (3)


Alergia ocular

Navarrete-Rodrígueza E, Sienra-Monge JJL, Ureña-Ortiza R

Idioma: Español
Referencias bibliográficas: 50
Paginas: 7-16
Archivo PDF: 253.38 Kb.


RESUMEN

La alergia ocular consiste en un grupo de enfermedades caracterizadas por inflamación de la conjuntiva ocular, dentro de las que podemos encontrar a la conjuntivitis alérgica estacional (CAE) o perenne (CAP), la queratoconjuntivitis vernal, la queratoconjuntivitis atópica y la blefaroconjuntivitis de contacto. Aqueja aproximadamente al 10% de la población mundial, y los más afectados son pacientes con otras patologías alérgicas. El diagnóstico es clínico y se integra mediante los síntomas y hallazgos encontrados durante la exploración física oftalmológica presentes en el sujeto al momento de la visita.
Los principales objetivos del tratamiento en la conjuntivitis alérgica son minimizar y controlar los signos y síntomas de la enfermedad, incluyendo la reducción del prurito, de la hiperemia y del edema de la conjuntiva y párpados, así como mejorar la calidad de vida del paciente. El tratamiento incluye medidas no farmacológicas, como evitar estímulos irritantes, el uso de lágrimas artificiales, la aplicación de compresas frías y medicamentos como vasoconstrictores, antihistamínicos, estabilizadores de mastocitos, agentes de acción dual, esteroides y fármacos inmunomoduladores, así como inmunoterapia alérgeno específica.
Los cambios desencadenados por la inflamación de la conjuntiva, producen daño corneal mecánico, y en los casos graves y crónicos de la enfermedad, el daño corneal puede resultar en la disminución de la agudeza visual, lo cual disminuye la calidad de vida del paciente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sánchez-Hernández MC, Montero J, Rondon C, Benitez del Castillo JM, Velázquez E, Herreras JM, et al. Consensus document on allergic conjunctivitis (DECA). J Investig Allergol Clin Immunol. 2015;25(2):94-106.

  2. Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak-Czechowicz M, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy. 2012 Nov;67(11):1327-37.

  3. Leonardi A, Castegnaro A, Valerio AL, Lazzarini D. Epidemiology of allergic conjunctivitis: clinical appearance and treatment patterns in a population-based study. Curr Opin Allergy Clin Immunol. 2015 Oct;15(5):482-8.

  4. Friedlaender MH. Ocular allergy. Curr Opin Allergy Clin Immunol. 2011 Oct;11(5):477-82

  5. Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol. 2010 Oct;126(4):778-783.e6.

  6. Brémond-Gignac D. The clinical spectrum of ocular allergy. Curr Allergy Asthma Rep. 2002 Jul;2(4):321-4.

  7. Friedlaender MH. Current concepts in ocular allergy. Ann Allergy. 1991 Jul;67(1):5-10, 13.

  8. Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol. 2000 Dec; 106(6):1019-32.

  9. Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2011 Oct;11(5):471-6.

  10. Bielory L, Meltzer EO, Nichols KK, Melton R, Thomas RK, Bartlett JD. An algorithm for the management of allergic conjunctivitis. Allergy Asthma Proc. 2013 Sep-Oct; 34(5):408-20.

  11. Hodges MG, Keane-Myers AM. Classification of ocular allergy. Curr Opin Allergy Clin Immunol. 2007 Oct;7(5): 424-8.

  12. Bielory L. Ocular allergy. Mt Sinai J Med. 2011 Sep-Oct; 78(5):740-58.

  13. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol. 1990 Jan;108(1):84-8.

  14. Leonardi A, Borghesan F, Faggian D, Depaoli M, Secchi AG, Plebani M. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol. 2000 Feb;129(2):151-8.

  15. Miyazaki D, Nakamura T, Toda M, Cheung-Chau KW, Richardson RM, Ono SJ. Macrophage inflammatory protein- 1alpha as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions. J Clin Invest. 2005 Feb;115(2):434-42.

  16. Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am. 2008 Feb;28(1):43-58, vi.

  17. Kari O, Saari KM. Diagnostics and new developments in the treatment of ocular allergies. Curr Allergy Asthma Rep. 2012 Jun;12(3):232-9.

  18. Goldberg A, Confino-Cohen R, Waisel Y. Allergic responses to pollen of ornamental plants: high incidence in the general atopic population and especially among flower growers. J Allergy Clin Immunol. 1998 Aug;102(2):210-4.

  19. Miraldi Utz V, Kaufman AR. Allergic eye disease. Pediatr Clin North Am. 2014 Jun;61(3):607-20

  20. Lambiase A, Minchiotti S, Leonardi A, Secchi AG, Rolando M, Calabria G, Orsoni J, et al. Prospective, multicenter demographic and epidemiological study on vernal keratoconjunctivitis: a glimpse of ocular surface in Italian population. Ophthalmic Epidemiol. 2009 Jan-Feb;16(1):38-41.

  21. Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol. 2008 Sep;153 Suppl 1:17-21.

  22. Ostler HB. Vernal conjunctivitis. In Diseases of the external eye and adnexae: a text and atlas. 1st ed. Baltimore: Williams & Wilkins; 1993. p. 125

  23. Kumar S1. Vernal keratoconjunctivitis: a major review. Acta Ophthalmol. 2009 Mar;87(2):133-47.

  24. Pattnaik L, Acharya L. A comprehensive review on vernal keratoconjunctivitis with emphasis on proteomics. Life Sci. 2015 May 1;128:47-54

  25. Sánchez MC, Fernández Parra B, Matheu V, Navarro A, Ibáñez MD, Dávila I, Dordal MT, et al. Allergic Conjunctivitis. J Investig Allergol Clin Immunol. 2011;21, Suppl. 2:1-19

  26. Foster CS, Calonge M. Atopic keratoconjunctivitis. Ophthalmology. 1990 Aug;97(8):992-1000.

  27. Bonini S. Atopic keratoconjunctivitis. Allergy. 2004 Aug;59 Suppl 78:71-3.

  28. La Rosa M, Lionetti E, Reibaldi M, Russo A, Longo A, Leonardi S, et al. Allergic conjunctivitis: a comprehensive review of the literature. Ital J Pediatr. 2013 Mar 14;39:18

  29. Bielory L. Differential diagnoses of conjunctivitis for clinical allergist-immunologists. Ann Allergy Asthma Immunol. 2007 Feb;98(2):105-14; quiz 114-7, 152.

  30. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and Allergen. Allergy. 2008;63 (Suppl 86):8-160.

  31. Valero A, Ferrer M, Sastre J, Navarro AM, Monclús L, Martí-Guadaño E, et al. A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items. J Allergy Clin Immunol. 2007;120:359-65

  32. Esposito S, Fior G, Mori A, Osnaghi S, Ghiglioni D. An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis. Paediatr Drugs. 2016 Oct;18(5):347-55

  33. Bielory L. Ocular allergy treatment. Immunol Allergy Clin North Am. 2008 Feb;28(1):189-224.

  34. Kumar S, Gupta N, Vivian AJ. Modern approach to managing vernal keratoconjunctivitis. Curr Allergy Asthma Rep. 2010;10:155-62.

  35. Berger WE, Granet DB, Kabat AG. Diagnosis and management of allergic conjunctivitis in pediatric patients. Allergy Asthma Proc. 2017 Jan 1;38(1):16-27.

  36. Ackerman S, Smith LM, Gomes PJ. Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Ther Adv Chronic Dis. 2016 Jan;7(1):52-67.

  37. Leonardi A, Piliego F, Castegnaro A, Lazzarini D, La Gloria Valerio A, Mattana P, et al. Allergic conjunctivitis: a cross-sectional study. Clin Exp Allergy. 2015 Jun;45(6): 1118-25.

  38. Leonardi A. Management of Vernal Keratoconjunctivitis. Ophthalmol Ther 2013;2:73-88.

  39. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 67. 2005;65:215-28.

  40. Abelson MB, McLaughlin JT, Gomes PJ. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep. 2011;11:205-11.

  41. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466-76.

  42. Abelson M, Welch D. An evaluation of onset and duration of action of patanol [olopatadine hydrochloride ophthalmic solution 0.1%] compared to claritin [loratadine 10 mg] tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl. 2000;78:60-3.

  43. Abelson M, Gomes P, Vogelson C, Pasquine T, Gross R, Turner F, et al. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. Clin Ther. 2004b;1237-48.

  44. Lanier B, Abelson M, Berger W, Granet D, D’Arienzo P, Spangler D, et al. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clin Ther. 2002;24:1161-74.

  45. Butrus S, Greiner J, Discepola M, Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther. 2000;22:1462-72.

  46. Katelaris C, Ciprandi G, Missotten L, Turner F, Bertin D, Berdeaux G. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther. 2002;24:1561-75.

  47. Yaylali V, Demirlenk I, Tatlipinar S, Ozbay D, Esme A, Yildirim C, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand. 2003;81:378-82.

  48. Bielory B, Perez V, Bielory L. Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Current Opinion in Allergy and Clinical Immunology. 2010;10:469-77.

  49. Erdinest N, Solomon A. Topical immunomodulators in the management of allergic eye diseases. Curr Opin Allergy Clin Immunol. 2014;14:457-63.

  50. Doan S, Amat F, Gabison E, Saf S, Cochereau I, Just J. Omalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature. Ophthalmol Ther. 2017 Jun;6(1):195-206.




2020     |     www.medigraphic.com